Eileen R. Faulds

Dr. Eileen R. Faulds


Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2021 in Diabetes Care
Verified
Journal Article
Open access
PDF file
GDGeorgia M. Davis
Georgia M. Davis
EFEileen R. Faulds
Eileen R. Faulds
TWTara Walker
Tara Walker
DVDebbie Vigliotti
Debbie Vigliotti
MRMarina Rabinovich
Marina Rabinovich
FPFrancisco Pasquel
Francisco Pasquel
OBJECTIVE: The use of remote real-time continuous glucose monitoring (CGM) in the hospital has rapidly emerged to preserve personal protective equipment and reduce potential exposures during coronavirus disease 2019 (COVID-19). RESEARCH DESIGN AND METHODS: We linked a hybrid CGM and point-of-care (POC) glucose testing protocol to a computerized decision support system for continuous insulin infusion and integrated a validation system for sensor glucose values into the electronic health record. We report our proof-of-concept experience in a COVID-19 intensive care unit. RESULTS: All nine patients required mechanical ventilation and corticosteroids. During the protocol, 75.7% of sensor values were within 20% of the reference POC glucose with an associated average reduction in POC of 63%. Mean time in range (70–180 mg/dL) was 71.4 ± 13.9%. Sensor accuracy was impacted by mechanical interferences in four patients. CONCLUSIONS: A hybrid protocol integrating real-time CGM and POC is helpful for managing critically ill patients with COVID-19 requiring insulin infusion.

8 June 2021 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Open access
PDF file
EFEileen R. Faulds
Eileen R. Faulds
ABAndrew Boutsicaris
Andrew Boutsicaris
LSLyndsey Sumner
Lyndsey Sumner
LJLaureen Jones
Laureen Jones
MMMolly McNett
Molly McNett
KDKathleen Dungan
Kathleen Dungan
Context: The coronavirus disease 2019 (COVID-19) pandemic has created a need for remote blood glucose (BG) monitoring in the intensive care unit (ICU).Objective: To evaluate feasibility and patient safety of a hybrid monitoring strategy of point-of-care (POC) BG plus continuous glucose monitor (CGM) in the ICU.Design: Retrospective analysis.Setting: ICU of an academic medical center.Patients: Patients with COVID-19 on IV insulin.Intervention: After meeting initial validation criteria, CGM was used for IV insulin titration and POC BG was performed every 6 hours or as needed.Main Outcome Measures: Outcomes included frequency of POC BG, workflow, safety, and accuracy measures.Results: The study included 19 patients, 18 with CGM data, mean age 58 years, 89% on mechanical ventilation, 37% on vasopressors, and 42% on dialysis. The median time to CGM validation was 137 minutes (interquartile range [IQR] 114-206). During IV insulin, the median number of POC values was 7 (IQR 6-16) on day 1, and declined slightly thereafter (71% reduction compared with standard of 24/day). The median number of CGM values used nonadjunctively to titrate IV insulin was 11.5 (IQR 0, 15) on day 1 and increased thereafter. Time in range 70 to 180 mg/dL was 64 ± 23% on day 1 and 72 ± 16% on days 2 through 7, whereas time <70 mg/dL was 1.5 ± 4.1% on day 1 and <1% on days 2 through 7.Conclusions: This study provides data to support that CGM using a hybrid protocol is feasible, accurate, safe, and has potential to reduce nursing and staff workload.

1 April 2021 in Endocrine Practice
Verified
Journal Article
Closed access
EFEileen R. Faulds
Eileen R. Faulds
LJLaureen Jones
Laureen Jones
MMMolly Mcnett
Molly Mcnett
KSKeaton Smetana
Keaton Smetana
CMCasey C. May
Casey C. May
KDKathleen Dungan
Kathleen Dungan

7 July 2022 in Current Diabetes Reports
Verified
Journal Article
Closed access
PDF file
EBElizabeth O. Buschur
Elizabeth O. Buschur
EFEileen R. Faulds
Eileen R. Faulds
KDKathleen Dungan
Kathleen Dungan

1 May 2019 in Endocrine Practice
Verified
Journal Article
Closed access
EFEileen R. Faulds
Eileen R. Faulds
JZJanet Zappe
Janet Zappe
KDKathleenbn M. Dungan
Kathleenbn M. Dungan

20 April 2023 in Journal of Diabetes Science and Technology
Verified
Journal Article
Closed access
LGLizda Guerrero-Arroyo
Lizda Guerrero-Arroyo
EFEileen R. Faulds
Eileen R. Faulds
MPM. Citlalli Perez-Guzman
M. Citlalli Perez-Guzman
GDGeorgia M. Davis
Georgia M. Davis
KDKathleen Dungan
Kathleen Dungan
FPFrancisco Pasquel
Francisco Pasquel
Traditionally, the care of critically ill patients with diabetes or stress hyperglycemia in the intensive care unit (ICU) demands the use of continuous intravenous insulin (CII) therapy to achieve narrow glycemic targets. To reduce the risk of iatrogenic hypoglycemia and to achieve glycemic targets during CII, healthcare providers (HCP) rely on hourly point-of-care (POC) arterial or capillary glucose tests obtained with glucose monitors. The burden of this approach, however, was evident during the beginning of the pandemic when the immediate reduction in close contact interactions between HCP and patients with COVID-19 was necessary to avoid potentially life-threatening exposures. Taking advantage of the advancements in current diabetes technologies, including continuous glucose monitoring (CGM) devices integrated with digital health tools for remote monitoring, HCP implemented novel protocols in the ICU to care for patients with COVID-19 and hyperglycemia. We provide an overview of research conducted in the ICU setting with the use of initial CGM technology to current devices and summarize our recent experience in the ICU.